Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections.
Identifieur interne : 004E83 ( Ncbi/Curation ); précédent : 004E82; suivant : 004E84Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections.
Auteurs : C. Sankhla [États-Unis] ; Joseph Jankovic [États-Unis] ; D. DuaneSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1998.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Animals, Antibody Specificity, Botulinum Toxins (immunology), Botulinum Toxins (therapeutic use), Botulinum Toxins, Type A (immunology), Botulinum Toxins, Type A (therapeutic use), Drug Resistance (immunology), Dystonia (drug therapy), Dystonia (immunology), Female, Humans, Immunologic Memory, Longitudinal Studies, Male, Mice, Middle Aged, Neuromuscular Agents (immunology), Neuromuscular Agents (therapeutic use), Treatment Outcome.
- MESH :
- chemical , immunology : Botulinum Toxins, Botulinum Toxins, Type A, Neuromuscular Agents.
- chemical , therapeutic use : Botulinum Toxins, Botulinum Toxins, Type A, Neuromuscular Agents.
- drug therapy : Dystonia.
- immunology : Drug Resistance, Dystonia.
- Aged, Aged, 80 and over, Animals, Antibody Specificity, Female, Humans, Immunologic Memory, Longitudinal Studies, Male, Mice, Middle Aged, Treatment Outcome.
Abstract
Immunoresistance (Ab+) to botulinum toxin type A (BTX-A) has been a serious concern since the introduction of BTX-A in the treatment of dystonia and other disorders associated with abnormal muscle contractions. We studied seven patients who developed Ab+ and later reverted to antibody-negative (Ab-) status. These seven patients, six women (mean age, 56 years; range, 41-80 years), with an average duration of dystonia for all patients of 197 months (range, 84-360 months), received a total mean cumulative dose of 1659 units (U) (range, 810-1975 U), with an average dose of 207 U per visit. All of these patients became unresponsive to BTX-A treatment and became Ab+ as determined by mouse bioassay. Their response to BTX-A after they reverted to Ab- was analyzed. The average latency between the initial BTX-A treatment and development of Ab+ was 27 months (range, 1543 months). The average duration between the detection of Ab+ status and subsequent reversal to Ab- status was 30 months (range, 10-78 months). Six of these Ab- patients were reinjected with BTX-A, and all six benefited from repeat injections comparable with their earlier response. Three patients lost their clinical response to subsequent injections and were found to be again Ab+. Two of the five patients who became immunoresistant to BTX-A received botulinum toxin type F (BTX-F) injections and one patient received a single session of BTX-B with improvement in their symptoms. In conclusion, this unique group of patients who were Ab+ and became Ab- responded favorably to repeat BTX-A injections, but some lost the benefit with subsequent injections. These observations suggest that the anamnestic immunologic response to BTX-A can wane, but can be reactivated by repeat BTX-A treatments. The presence of antibodies did not interfere with the response to BTX-F or BTX-B injections, thus confirming the antigenic specificity of various BTX serotypes.
DOI: 10.1002/mds.870130128
PubMed: 9452341
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :004502
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :004502
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :004302
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :004E83
Links to Exploration step
pubmed:9452341Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections.</title>
<author><name sortKey="Sankhla, C" sort="Sankhla, C" uniqKey="Sankhla C" first="C" last="Sankhla">C. Sankhla</name>
<affiliation wicri:level="1"><nlm:affiliation>Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030</wicri:regionArea>
<wicri:noRegion>Texas 77030</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J" last="Jankovic">Joseph Jankovic</name>
<affiliation><country>États-Unis</country>
<placeName><settlement type="city">Houston</settlement>
<region type="state">Texas</region>
</placeName>
<orgName type="university" n="3">Baylor College of Medicine</orgName>
</affiliation>
</author>
<author><name sortKey="Duane, D" sort="Duane, D" uniqKey="Duane D" first="D" last="Duane">D. Duane</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1998">1998</date>
<idno type="RBID">pubmed:9452341</idno>
<idno type="pmid">9452341</idno>
<idno type="doi">10.1002/mds.870130128</idno>
<idno type="wicri:Area/PubMed/Corpus">004502</idno>
<idno type="wicri:Area/PubMed/Curation">004502</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004302</idno>
<idno type="wicri:Area/Ncbi/Merge">004E83</idno>
<idno type="wicri:Area/Ncbi/Curation">004E83</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections.</title>
<author><name sortKey="Sankhla, C" sort="Sankhla, C" uniqKey="Sankhla C" first="C" last="Sankhla">C. Sankhla</name>
<affiliation wicri:level="1"><nlm:affiliation>Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030</wicri:regionArea>
<wicri:noRegion>Texas 77030</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J" last="Jankovic">Joseph Jankovic</name>
<affiliation><country>États-Unis</country>
<placeName><settlement type="city">Houston</settlement>
<region type="state">Texas</region>
</placeName>
<orgName type="university" n="3">Baylor College of Medicine</orgName>
</affiliation>
</author>
<author><name sortKey="Duane, D" sort="Duane, D" uniqKey="Duane D" first="D" last="Duane">D. Duane</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1998" type="published">1998</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Animals</term>
<term>Antibody Specificity</term>
<term>Botulinum Toxins (immunology)</term>
<term>Botulinum Toxins (therapeutic use)</term>
<term>Botulinum Toxins, Type A (immunology)</term>
<term>Botulinum Toxins, Type A (therapeutic use)</term>
<term>Drug Resistance (immunology)</term>
<term>Dystonia (drug therapy)</term>
<term>Dystonia (immunology)</term>
<term>Female</term>
<term>Humans</term>
<term>Immunologic Memory</term>
<term>Longitudinal Studies</term>
<term>Male</term>
<term>Mice</term>
<term>Middle Aged</term>
<term>Neuromuscular Agents (immunology)</term>
<term>Neuromuscular Agents (therapeutic use)</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Botulinum Toxins</term>
<term>Botulinum Toxins, Type A</term>
<term>Neuromuscular Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Botulinum Toxins</term>
<term>Botulinum Toxins, Type A</term>
<term>Neuromuscular Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dystonia</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Drug Resistance</term>
<term>Dystonia</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Animals</term>
<term>Antibody Specificity</term>
<term>Female</term>
<term>Humans</term>
<term>Immunologic Memory</term>
<term>Longitudinal Studies</term>
<term>Male</term>
<term>Mice</term>
<term>Middle Aged</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Immunoresistance (Ab+) to botulinum toxin type A (BTX-A) has been a serious concern since the introduction of BTX-A in the treatment of dystonia and other disorders associated with abnormal muscle contractions. We studied seven patients who developed Ab+ and later reverted to antibody-negative (Ab-) status. These seven patients, six women (mean age, 56 years; range, 41-80 years), with an average duration of dystonia for all patients of 197 months (range, 84-360 months), received a total mean cumulative dose of 1659 units (U) (range, 810-1975 U), with an average dose of 207 U per visit. All of these patients became unresponsive to BTX-A treatment and became Ab+ as determined by mouse bioassay. Their response to BTX-A after they reverted to Ab- was analyzed. The average latency between the initial BTX-A treatment and development of Ab+ was 27 months (range, 1543 months). The average duration between the detection of Ab+ status and subsequent reversal to Ab- status was 30 months (range, 10-78 months). Six of these Ab- patients were reinjected with BTX-A, and all six benefited from repeat injections comparable with their earlier response. Three patients lost their clinical response to subsequent injections and were found to be again Ab+. Two of the five patients who became immunoresistant to BTX-A received botulinum toxin type F (BTX-F) injections and one patient received a single session of BTX-B with improvement in their symptoms. In conclusion, this unique group of patients who were Ab+ and became Ab- responded favorably to repeat BTX-A injections, but some lost the benefit with subsequent injections. These observations suggest that the anamnestic immunologic response to BTX-A can wane, but can be reactivated by repeat BTX-A treatments. The presence of antibodies did not interfere with the response to BTX-F or BTX-B injections, thus confirming the antigenic specificity of various BTX serotypes.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004E83 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 004E83 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Ncbi |étape= Curation |type= RBID |clé= pubmed:9452341 |texte= Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:9452341" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
This area was generated with Dilib version V0.6.23. |